Intratumoral DNA stem-line heterogeneity in superficial spreading melanoma - 21/08/11
, Dirk Altrichter, MD, Thomas Klapperstück, PhD, Wolfgang Ch. Marsch, MD
Reprints not available from the authors. Correspondence to: Peter Helmbold, MD, Department of Dermatology and Venereology, Martin Luther University Halle–Wittenberg, Ernst-Kromayer Str 5, D-06097 Halle (Saale), Germany.Halle, Germany
Abstract |
Background |
In primary melanomas, data on the degree of intratumoral heterogeneity to date have been lacking.
Objective |
Our purpose was to investigate intratumoral DNA stem-line heterogeneity in superficial spreading melanoma (SSM).
Methods |
Multiple measuring fields of 54 SSMs (tumor thickness median 1.60 mm) were studied by DNA image cytometry to obtain data on the number of DNA stem lines per tumor, their ploidy characteristics, and intratumoral distribution. Results were compared with standard histopathological criteria.
Results |
Twenty-three of 54 SSMs were found to have two or three distinct proliferating tumor cell stem lines (1.46 ± 0.57 per tumor). Stem lines appeared spatially separated in 22 of 23 SMMs. At least 3 measuring fields per tumor were necessary to identify all stem lines with a likelihood of 95%. DNA heterogeneity correlated with tumor thickness, but occurred in 5 of 19 cases of pT1 melanoma.
Conclusions |
Primary SSMs can be regarded as potentially clonally unstable with a tendency for spatial separation of tumor cell stem lines.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by the Ministry of Education and the Arts of the State of Saxony-Anhalt, Germany. Conflicts of interest: None. |
Vol 52 - N° 5
P. 803-809 - mai 2005 Retour au numéro
Article précédent
- Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma
- Darius J. Karimipour, Jennifer L. Schwartz, Timothy S. Wang, Christopher K. Bichakjian, Jeffrey S. Orringer, Anya L. King, Conway C. Huang, Timothy M. Johnson
- Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies
- Amy S. Paller, Mark Lebwohl, Alan B. Fleischer, Richard Antaya, Richard G. Langley, Robert S. Kirsner, Robin R. Blum, M. Joyce Rico, Eileen Jaracz, Andrew Crowe, Gregory J. Linowski, for the US/Canada Tacrolimus Ointment Study Group ∗
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?